Marshall Wace, LLP Immuno Gen, Inc. Transaction History

Marshall Wace, LLP

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$12.46 - $29.95 $14.8 Million - $35.6 Million	1,187,027 New	1,187,027 $35.2 Million
Q1 2023 May 15, 2023	SELL	$3.67 - $4.92 $418,600 - $561,175	-114,060 Reduced 49.94%	114,355 $439,000
Q4 2022 Feb 14, 2023	SELL	$4.55 - $6.31 $35,421 - $49,123	-7,785 Reduced 3.3%	228,415 $1.13 Million
Q3 2022 Nov 14, 2022	BUY	$4.48 - $6.47 $1.06 Million - $1.53 Million	236,200 New	236,200 $1.13 Million
Q2 2021 Aug 13, 2021	SELL	$5.79 - $8.6 $3.03 Million - $4.5 Million	-523,087 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$6.5 - $10.53 $3.4 Million - $5.51 Million	523,087 New	523,087 $4.24 Million
Q2 2020 Aug 13, 2020	SELL	$3.32 - $5.34 $580,731 - $934,067	-174,919 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$2.12 - $6.8 $129,292 - $414,711	60,987 Added 53.53%	174,919 $597,000
Q4 2019 Feb 14, 2020	BUY	$2.25 - $5.8 $256,347 - $660,805	113,932 New	113,932 $582,000
Q3 2019 Nov 14, 2019	SELL	$2.22 - $3.39 $320,774 - $489,831	-144,493 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$1.8 - $3.3 $260,087 - $476,826	144,493 New	144,493 $314,000
Q1 2019 May 14, 2019	SELL	$2.41 - $5.91 $630,475 - $1.55 Million	-261,608 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$3.94 - $9.7 $1.03 Million - $2.54 Million	261,608 New	261,608 $1.26 Million

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.